2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.01 Prognostic Significance of Purinergic Receptor- and Ectonucleotidase- Expression in NSCLC Tumor Cells and Stroma

EP.06G.01 Prognostic Significance of Purinergic Receptor- and Ectonucleotidase- Expression in NSCLC Tumor Cells and Stroma

Back to course

Pdf Summary

The study examines the prognostic significance of purinergic receptor and ectonucleotidase expression in non-small cell lung cancer (NSCLC) tumor cells and stroma. Taking place between 2014 and 2017 at the University Medical Center Freiburg, the retrospective cohort study involved 142 NSCLC patients who underwent surgical treatment. Researchers utilized immunohistochemical staining for P2X4, P2X7, CD39, and CD73 to classify tissue samples into high or low expression groups based on H-Scores, aiming to correlate these expressions with overall survival (OS) and progression-free survival (PFS).<br /><br />Findings revealed that high expression of CD39 in both tumor cells and stroma significantly associated with prolonged progression-free survival. Conversely, low expression of CD73 was linked to longer overall survival. Secondary endpoints explored correlations with clinical parameters like tumor size and metastasis. Specifically, low CD39 expression was significantly associated with worse prognosis, as well as indicators such as larger tumor size, higher SUVmax, and higher incidence of metastasis and relapse.<br /><br />The study concludes that purinergic signaling markers, especially ectonucleotidases CD39 and CD73, strongly correlate with NSCLC survival rates and clinical outcomes. These findings suggest these molecules could potentially serve as therapeutic targets. Given the correlations observed, further research into the role of these biomarkers in tumor biology and their potential as treatment targets is recommended. The study highlights the complexity of the tumor microenvironment and the importance of understanding molecular markers in improving NSCLC prognosis and therapy.

Asset Subtitle

Sophie Prozmann

Meta Tag

Speaker Sophie Prozmann

Topic Pathology and Biomarkers

Keywords

NSCLC

purinergic receptor

ectonucleotidase

CD39

CD73

tumor microenvironment

prognostic significance

immunohistochemical staining

survival rates

therapeutic targets